Advances in Therapy

, Volume 28, Issue 11, pp 986–999

Idiopathic pulmonary fibrosis: Treatment update

  • Oisin J. O’Connell
  • Marcus P. Kennedy
  • Michael T. Henry
Review

DOI: 10.1007/s12325-011-0066-5

Cite this article as:
O’Connell, O.J., Kennedy, M.P. & Henry, M.T. Adv Therapy (2011) 28: 986. doi:10.1007/s12325-011-0066-5

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias. Despite multiple recent clinical trials, there is no strong evidence supporting a survival advantage for any agent in the management of patients with IPF. The limited effectiveness of current treatment regimes has led to a search for novel therapies including antifibrotic strategies. This article reviews the evidence supporting the treatments currently used in the management of IPF.

Keywords

antifibrotic idiopathic pulmonary fibrosis patient management treatment 

Copyright information

© Springer Healthcare 2011

Authors and Affiliations

  • Oisin J. O’Connell
    • 1
  • Marcus P. Kennedy
    • 1
  • Michael T. Henry
    • 1
  1. 1.Department of Respiratory MedicineCork University HospitalWilton, CorkIreland

Personalised recommendations